Denosumab associated with accelerated progression of abdominal aortic calcification among patients on dialysis
Authors' conclusion
Although denosumab is beneficial for bone health in patients on dialysis, its vascular effects warrant careful monitoring.
Study context
- Population
- Patients on dialysis
- Participants
- 25 vs 21
- Exposure
- Denosumab vs no denosumab in dialysis patients
- Denosumabn = 25
- Controln = 21reference
- Outcome
- Change in abdominal aortic calcification (CT calcification volume and Agatston score) and BMD
- Follow-up
- 2 yr
Methodological detailsBMD assessed at 1-yr intervals; abdominal aortic calcification evaluated by CT
- BMD assessed at 1-yr intervals; abdominal aortic calcification evaluated by CT
Main finding
As reported in the abstract
Rate of increase from baseline in abdominal aortic calcification volume
P = 0.0476
Observational data: associations, not effects.
Further findings
Rate of increase from baseline in Agatston score · 2 yr · higher with Denosumab
P = 0.0483
BMD increase at LS
P = 0.0079
Original publication
Denosumab associated with accelerated progression of abdominal aortic calcification among patients on dialysis. J Bone Miner Res. Published 10 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →